TRCT
INAB icon

Tower Research Capital (TRC)’s IN8bio INAB Stock Holding History

Tower Research Capital (TRC)’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.27K Buy
3,738
+2,473
+195% +$3.73K ﹤0.01% 4287
2026
Q1 		$1.87K Sell
1,265
-1,185
-48% -$2.29K ﹤0.01% 4591
2025
Q4 		$5.73K Sell
2,450
-605
-20% -$1.15K ﹤0.01% 4100
2025
Q3 		$6.63K Buy
3,055
+1,538
+101% +$3.38K ﹤0.01% 4149
2025
Q2 		$3.17K Buy
1,517
+841
+124% +$3.42K ﹤0.01% 4539
2025
Q1 		$3.37K Buy
676
+57
+9% +$455 ﹤0.01% 4426
2024
Q4 		$4.77K Buy
619
+179
+41% +$1.57K ﹤0.01% 4399
2024
Q3 		$3.56K Buy
440
+314
+249% +$5.69K ﹤0.01% 4823
2024
Q2 		$3.21K Sell
126
-237
-65% -$7.61K ﹤0.01% 4922
2024
Q1 		$12.9K Buy
363
+160
+79% +$6.04K ﹤0.01% 3440
2023
Q4 		$8.4K Sell
203
-188
-48% -$6.01K ﹤0.01% 4514
2023
Q3 		$12.2K Buy
391
+165
+73% +$6.19K ﹤0.01% 3918
2023
Q2 		$10.4K Buy
226
+63
+39% +$3.94K ﹤0.01% 4121
2023
Q1 		$6K Sell
163
-59
-27% -$3.29K ﹤0.01% 4846
2022
Q4 		$15K Buy
222
+161
+264% +$9.01K ﹤0.01% 3420
2022
Q3 		$4K Sell
61
-12
-16% -$806 ﹤0.01% 5259
2022
Q2 		$5K Sell
73
-40
-35% -$3.38K ﹤0.01% 5057
2022
Q1 		$11K Buy
113
+7
+7% +$783 ﹤0.01% 4179
2021
Q4 		$14K Buy
106
+9
+9% +$1.78K ﹤0.01% 4077
2021
Q3 		$20K Buy
+97
New +$24.1K ﹤0.01% 3711

Other funds holding INAB

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Tower Research Capital (TRC)'s INAB Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its IN8bio (INAB) stake by 195% in Q2 2026, buying an estimated $3.73K and bringing the position to 3,738 shares worth $5.27K. The position accounts for ﹤0.01% of the portfolio, ranked #4287.

Tower Research Capital (TRC) first reported a position in INAB in Q3 2021 and has held it in 20 quarters since. The position peaked at $20K in Q3 2021. 21 funds tracked by Wall St. Rank hold INAB as of Q2 2026.

  • Tower Research Capital (TRC) held 3,738 shares of IN8bio worth $5.27K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,473 IN8bio shares in Q2 2026, an estimated $3.73K.
  • IN8bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4287 holding.
  • Tower Research Capital (TRC) first reported a position in IN8bio in Q3 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s IN8bio position peaked at $20K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held IN8bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.